Colorado School of Mines, Golden, USA;APEX Research/Family Medicine, Denver, USA
APEX Research/Family Medicine, Denver, USA
GlaxoSmithKline, Research Triangle Park, USA
GlaxoSmithKline, Research Triangle Park, USA
APEX Research/Family Medicine, Denver, USA;International Association of Providers of AIDS Care, Washington, USA
Copyright © 2014 Linda Battalora, Amy Thomas, Brian Wine, Belinda Ha, Benjamin Young et al. This is
an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
How to Cite this Article
Battalora, L. , Thomas, A. , Wine, B. , Ha, B. and Young, B. (2014) Changes in Bone Mineral Density through 96 Weeks in Antiretroviral-Naïve HIV-1 Infected Patients Receiving Abacavir/Lamivudine and Raltegravir in the SHIELD Trial.
World Journal of AIDS,
4, 38-44. doi:
10.4236/wja.2014.41005.